Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP006: Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCOECCO '17 Barcelona
Year: 2017
Authors:

Sigall Boneh R.1, Levine A.1,2, Lomer M.3, Wierdsma N.4, Alan P.5, Fiorino G.6, Gatti S.7, Jonkers D.8, Kierkus J.9, Katsanos K.H.10, Melgar S.11, Saritas Yuksel E.12, Whelan K.13, Wine E.14, Gerasimidis K.*15

1Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel 2Tel Aviv University, Tel Aviv, Israel 3Guy's and St Thomas' NHS Foundation Trust and King's College London, Department of Nutrition and Dietetics, London, United Kingdom 4VU University Medical Centre, Department of Nutrition and Dietetics, Amsterdam, Netherlands 5John Radcliffe Hospital, Department of Translational Gastroenterology, Oxford, United Kingdom 6Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy 7Polytechnic University of Marche, Department of Paediatrics, Ancona, Italy 8NUTRIM School for Nutrition and Translation Research in Metabolism, Maastricht University Medical Center, Division Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht, Netherlands 9Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland 10University and Medical School of Ioannina, Department of Gastroenterology and Hepatology, Ioannina, Greece 11APC Microbiome Institute, University College Cork, Cork, Ireland 12Izmir Katip Celebi University Ataturk Teaching and Research Hospital, Department of Gastroenterology, Izmir, Turkey 13King's College London, Division of Diabetes and Nutritional Sciences, London, United Kingdom 14University of Alberta, Department of Paediatrics, Edmonton, Canada 15University of Glasgow, Human Nutrition, School of Medicine, Dentistry and Nursing, Glasgow, United Kingdom

DOP007: Crohn's disease exclusion diet and partial enteral nutrition (CDED+PEN) vs exclusive enteral nutrition (EEN). Microbiome changes of a randomized clinical trial (RCT) in pediatric CD: remission is associated with similar structural + functional profilesECCO '17 Barcelona
Year: 2017
Authors:

Dunn K.A.1, Sigall-Boneh R.2, Bielawski J.P.1, Turner D.3, Van Limbergen J.*4, Levine A.2

1Dalhousie University, Biology, Halifax, Canada 2Edith Wolfson Medical Centre, Pediatrics, Tel Aviv, Israel 3Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel 4IWK Health Centre - Dalhousie University, Pediatric Gastroenterology, Halifax, Canada

DOP008: Dietary manipulation of the healthy human and colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept studyECCO '17 Barcelona
Year: 2017
Authors:

Svolos V.1, Hansen R.2, Ijaz U.Z.3, Quince C.4, Watson D.5, Alghamdi A.5, Brejnrod A.4, Ansalone C.6, Milling S.6, Gaya D.7, Russell R.2, Gerasimidis K.*1

1Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom 2Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom 3School of Engineering, University of Glasgow, Glasgow, United Kingdom 4Warwick Medical School, University of Warwick, Warwick, United Kingdom 5Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom 6Institute of Infection, Immunity and Inflammation, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom 7Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom

DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosisECCO '17 Barcelona
Year: 2017
Authors:

Cohen-Dolev N.*1, Sladek M.2, Sigall Boneh R.1, Veres G.3, Hussey S.4, Staiano A.5, Nuti F.6, Lionetti P.7, Koletzko S.8, Levine A.1

1The E.Wolfson medical Center, Pediatric Gastroenterology and Nutrition Research Unit, Holon, Israel 2Jagiellonian University Medical College, Krakow, Poland 3Semmelweis University, Ist Dept. of Pediatrics, Budapest, Hungary 4National Children's Research Centre, UCD and RCSI, Dublin, Ireland 5University of Naples “Federico II”, Department of Translational Medical Science, Section of Pediatrics, Napoli, Italy 6Sapienza University, Rome, Italy 7University of Florence, Florence, Italy 8Dr. v Haunersches Kinderspital, Ludwig Maximilians University Munich, Department of Pediatric Gastroenterology and Hepatology, Munich, Germany

DOP010: ECCO topical review on transitional care in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

van Rheenen P. ECCO Transition Topical Review Consensus Group

University Medical Center Groningen, Pediatric Gastroenterology, Groningen, Netherlands

DOP011: Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAIDECCO '17 Barcelona
Year: 2017
Authors:

Gagniere C.*1, Bourrier A.2, Seksik P.2, Gornet J.-M.3, Dewit O.4, Nancey S.5, Altwegg R.6, Abitbol V.7, Laharie D.8, Reenaers C.9, Buisson A.10, Nachury M.11, Viennot S.12, Vuitton L.13, Stefanescu C.14, Marteau P.15, Bouguen G.16, Cosnes J.2, Amiot A.1

1Henri Mondor Hospital, Gastroenterology, Creteil, France 2APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France 3Hospital Saint-Louis, Department of Gastroenterology, Paris, France 4UCL Saint-Luc, Department of Gastroenterology, Brussels, Belgium 5Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France 6CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France 7Cochin Hospital, Department of Gastroenterology, Paris, France 8CHU Bordeaux, Department of Gastroenterology, Bordeaux, France 9CHU Liège, Sart Tilman, Department of Gastroenterology, Liège, Belgium 10CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France 11CHRU Lille, Department of Gastroenterology, Lille, France 12Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France 13CHU Besancon, Department of Gastroenterology and Hepatology, Besançon, France 14APHP Beaujon, Department of Gastroenterology, Clichy, France 15Hospital Lariboisière, Department of Gastroenterology, Paris, France 16CHU Pontchaillou, Department of Gastroenterology, Rennes, France

DOP012: Impact on clinical practice of Epstein-Barr virus infection in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

de Francisco R.*1, Riestra S.1, Pérez-Martínez I.1, Castaño A.1, Martínez-González S.1, Jiménez S.2, González A.J.3, Morais L.R.3, Suárez A.1

1Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain 2Hospital Universitario Central de Asturias, Pediatrics, Oviedo, Spain 3Hospital Universitario Central de Asturias, Hematology, Oviedo, Spain

DOP013: Definition of therapeutic response criteria using MRI in Crohn's disease patients treated with anti-TNF therapy: a multicenter prospective study (the IRMA study)ECCO '17 Barcelona
Year: 2017
Authors:

Buisson A.*1,2, Messadeg L.3, Bouguen G.4, Goutorbe F.1,5, Reimund J.-M.6, Goutte M.1,2, Sautel C.7, Duron C.8, Scanzi J.1, Reymond M.1, Allimant C.1, Dapoigny M.1, Bommelaer G.1,2, Pereira B.9, Hordonneau C.3

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 3University Hospital Estaing, Radiology Department, Clermont-Ferrand, France 4University Hospital, Rennes, France 5Hospital of Bayonne, Gastroenterology Department, Bayonne, France 6University Hospital Hautepierre, Gastroenterology Department, Strasbourg, France 7Hospital of Issoire, Gastroenterology Department, Issoire, France 8Hospital of Montluçon, Department of Gastroenterology, Montluçon, France 9University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France

DOP014: Transmural healing is better than mucosal healing in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Raimundo Fernandes S.*1, Vale Rodrigues R.2, Bernardo S.1, Cortez Pinto J.2, Rosa I.2, Correia L.1, Moura Santos P.3, Rita Gonçalves A.3, Valente A.3, Baldaia C.3, Pereira da Silva J.2, Dias Pereira A.2, Velosa J.1

1Hospital de Santa Maria, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal 2Instituto Português de Oncologia de Lisboa, Serviço de Gastrenterologia, Lisboa, Portugal 3Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

DOP015: International differences in gastroenterologists' perspective on stopping therapy for patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Siegel C.A.*1, Thompson K.D.1, Walls D.2, Gollins J.3, Colombel J.-F.4, Louis E.5 on behalf of the BIOCYCLE Group5

1Dartmouth-Hitchcock Medical Center, Lebanon, United States 2BDJ Solutions, Boston, United States 3Delta Modelling, Chicago, United States 4Icahn School of Medicine at Mount Sinai, New York, United States 5University Hospital CHU of Liège, Liège, Belgium

DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY studyECCO '17 Barcelona
Year: 2017
Authors:

Chaparro M.*1, Verreth A.2, Lobaton T.3, Gravito-Soares E.4, Julsgaard M.5, Savarino E.6, Magro F.7, Avni Biron I.8, Lόpez-Serrano P.9, Casanova M.1, Gompertz M.10, Vitor S.11, Arroyo M.12, Pugliese D.13, Zabana Y.14, Vicente R.15, Aguas M.16, Bar-Gil Shitrit A.17, Gutierrez A.18, Doherty G.19, Fernández-Salazar L.20, Martinez Cadilla J.21, Huguet J.22, O'Toole A.23, Stasi E.24, Manceñido Marcos N.25, Villoria A.26, Karmiris K.27, Rahier J.28, Rodriguez C.29, Diz-Lois Palomares M.30, Fiorino G.31, Benítez J.32, Principi M.33, Naftali T.34, Taxonera C.35, Mantzaris G.36, Sebkova L.37, Iade B.38, Lissner D.39, Ferrer Bradley I.40, Lόpez-San Román A.41, Marín-Jiménez I.42, Merino O.43, Sierra M.44, Van Domselaar M.45, Caprioli F.46, Guerra I.47, Peixe P.48, Piqueras M.49, Rodríguez-Lago I.50, Ber Y.51, Van Hoeve K.2, Torres P.3, Gravito-Soares E.4, Rudbeck-Thomsen D.5, Bartolo O.6, Peixoto A.7, Martín G.8, Pérez J.1, Garre A.1, Donday M.G.1, Martín de Carpi J.52, Gisbert J.P.1 Gastroenterology Units, on behalf of the TEDDY Study Group Investigators

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Madrid, Spain 2University Hospitals Leuven, Leuven, Belgium 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain 4Centro Hopitalar e Universitario de Coimbra, Coimbra, Portugal 5Aarhus University Hospital, Aarhus, Denmark 6University of Padua, Padua, Italy 7Centro Hospitalar Sao Joao, Porto, Portugal 8Rabin Medical Center, Petaj Tikva, Israel 9Hospital Universitario Fundaciόn Alcorcόn, Alcorcόn, Spain 10Hospital Clinic Barcelona, Barcelona, Spain 11Hospital de Santa Maria de Lisboa, Lisboa, Portugal 12Hospital Clínico de Zaragoza, Zaragoza, Spain 13Complesso Integrato Columbus Catholic University, Roma, Italy 14Hospital Universitari Mútua de Terrassa, Terrassa, Spain 15Hospital Universitario Miguel Servet, Zaragoza, Spain 16Hospital Universitario La Fe, Valencia, Spain 17Shaare Zedek Medical Center Jerusalem, Jerusalem, Israel 18Hospital General Universitario de Alicante, Alicante, Spain 19St. Vincents University Hospital, Dublin, Ireland 20Hospital Clínico Universitario de Valladolid, Spain, Valladolid, Spain 21Hospital Universitario Alvaro Cunqueiro, Vigo, Spain 22Hospital General Universitario de Valencia, Valencia, Spain 23Beaumont Hospital, Dublin, Ireland 24IRCCS Saverio de Bellis, Castellana Grotte, Italy 25Hospital Infanta Sofía, Madrid, Spain 26Hospital Parc Taulí, Sabadell, Spain 27Venizeleio General Hospital, Heraklion, Greece 28CHU Dinant Godinne, Dinant, Belgium 29Complejo Universitario de Navarra, Pamplona, Spain 30Hospital Universitario A Coruña, Coruña, Spain 31Humanitas Research Hospital, Milan, Italy 32Hospital Reina Sofia, Cόrdoba, Spain 33Azienda Ospedaliera Policlinico de Bari, Bari, Italy 34Meir Hospital Kfar saba Tel Aviv University, Tel Aviv, Israel 35Hospital Clínico San Carlos, Madrid, Spain 36Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Athens, Greece 37Azienda Ospedaliera “Pugliese-Ciaccio”, Catanzaro, Italy 38Hospital de Clínicas, Montevideo, Uruguay 39Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany 40Hospital de Manises, Manises, Spain 41Hospital Ramόn y Cajal, Madrid, Spain 42Hospital General Universitario Gregorio Marañon, Madrid, Spain 43Hospital Universitario de Cruces, Baracaldo, Spain 44Hospital de Leόn, Leόn, Spain 45Hospital de Torrejόn, Torrejόn de Ardoz, Spain 46IRCCS Ospedale Ca Granda Policlinico di Milano, Milano, Italy 47Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain 48Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal 49Consorci Sanitari de Terrasa, Terrasa, Spain 50Hospital de Galdakao, Vizcaya, Spain 51Hospital San Jorge, Huesca, Spain 52Hospital Sant Joan de Déu, Barcelona, Spain

DOP017: Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims dataECCO '17 Barcelona
Year: 2017
Authors:

Bots S.*1, Hoekman D.1,2, Benninga M.2, Ponsioen C.1, Smeets H.3, D'Haens G.1, Löwenberg M.1

1Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands 2Academic Medical Center (AMC), Department of Pediatric Gastroenterology and Nutrition, Amsterdam, Netherlands 3Achmea Health Insurance, Amersfoort, Netherlands

DOP018: Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADAECCO '17 Barcelona
Year: 2017
Authors:

Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7

1Oxford University Hospitals, Oxford, United Kingdom 2Robarts Research Institute, London, Canada 3University Hospital of Nancy, Les Nancy, France 4University of Calgary, Calgary, Canada 5Istituto Clinico Humanitas, Milan, Italy 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany 7AbbVie Inc., North Chicago, United States

DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysisECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.G.*1, Sandborn W.J.2, Colombel J.-F.3, O'Byrne S.4, Khalid J.M.5, Brayshaw N.6, Geransar P.7, Rubin D.T.8

1Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials Inc, London, Canada 2University of California San Diego, Division of Gastroenterology, La Jolla, United States 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 4Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, United Kingdom 5Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 6Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 7Takeda Pharmaceuticals International AG, Global Medical Affairs, Zürich, Switzerland 8University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States

DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumabECCO '17 Barcelona
Year: 2017
Authors:

Yarur A.*1, Bruss A.1, Jain A.2, Kondragunta2 V.2, Hester K.2, Luna T.2, Agrawal D.1, Patel A.1, Fox C.1, Werner S.1, Naik S.2, Stein D.1

1Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, United States 2Prometheus Laboratories, San Diego, United States

DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension studyECCO '17 Barcelona
Year: 2017
Authors:

Vermeire S.*1, Loftus E.V.2, Colombel J.-F.3, Feagan B.4, Sandborn W.5, Sands B.6, Danese S.7, D'Haens G.8, Kaser A.9, Panaccione R.10, Rubin D.11, Shafran I.12, O'Byrne S.13, Geransar P.13, Previtali A.14, Khalid J.M.15, Kaviya A.16

1University Hospitals Leuven, Dpt of Gastroenterology, Leuven, Belgium 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, United States 3Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 4Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 5University of California - San Diego, Division of Gastroenterology, La Jolla, United States 6Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States 7Humanitas University, Italy, Gastrointestinal Immunopathology, Milan, Italy 8Academic Medical Centre, Dept. of Gastroenterology, Amsterdam, Netherlands 9University of Cambridge, Division of Gastroenterology and Hepatology, Cambridge, United Kingdom 10University of Calgary, Department of Medicine, Calgary, Canada 11University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, United States 12Shafran Gastroenterology Research center, Gastroenterology, Winter Park, United States 13Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland 14Takeda Development Centre Europe Ltd, Global Statistics and Statistical Programming, London, United Kingdom 15Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 16Takeda Development Centre Europe Ltd, Clinical Development, London, United Kingdom

DOP022: Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart reviewECCO '17 Barcelona
Year: 2017
Authors:

Ehehalt R.*1, Schubert S.2, Stein D.3, Lambrelli D.4, Bassel M.5, Orzechowski H.-D.6, Minda K.7, Khalid J.M.8

1Gastroenterology Outpatient Clinic, Heidelberg, Germany 2Gastroenterologist in Private Practice, Berlin, Germany 3Evidera, Montreal, Canada 4Evidera, Hammersmith, United Kingdom 5UBC: An Express Scripts Company, Montreal, Canada 6Takeda Pharma GmbH, Berlin, Germany 7Takeda Pharmaceuticals International AG, Zurich, Switzerland 8Takeda Development Centre Europe Ltd, London, United Kingdom

DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortiumECCO '17 Barcelona
Year: 2017
Authors:

Dulai P.*1, Meserve J.1, Hartke J.2, Chilukuri P.2, Chaudrey K.3, Koliani-Pace J.L.4, Kochhar G.5, Parikh M.P.5, Shmidt E.6, Hirten R.6, Luo M.7, Barocas M.7, Lasch K.7, Sultan K.8, Swaminath A.9, Bohm M.10, Lukin D.11, Hudesman D.12, Shen B.5, Siegel C.A.4, Sands B.E.6, Colombel J.-F.6, Kane S.3, Loftus Jr. E.V.3, Singh S.1, Sandborn W.J.1, Boland B.S.1

1University of California - San Diego, La Jolla, United States 2Indiana University School of Medicine, Indianapolis, United States 3Mayo Clinic, Rochester, United States 4Dartmouth-Hitchcock Medical Center, Lebanon, United States 5Cleveland Clinic Foundation, Cleveland, United States 6Icahn School of Medicine at Mount Sinai, New York, United States 7Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States 8North Shore University Hospital, Manhasset, United States 9Lenox Hill Hospital, New York, United States 10Indiana University Hospital, Indianapolis, United States 11Albert Einstein College of Medicine, Montefiore Medical Center, New York, United States 12New York University School of Medicine, New York, United States

DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO '17 Barcelona
Year: 2017
Authors:

Ng S.C.*1, Palo W.2, Blake A.3, Rana-Khan Q.4, Bhayat F.5

1Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, Hong Kong 2Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States 3Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 4Takeda Pharmaceutical International AG Singapore, Emerging Markets Medical Affairs, Singapore, Singapore 5Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom

DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAIDECCO '17 Barcelona
Year: 2017
Authors:

Tadbiri S.*1, Grimaud J.C.2, Peyrin-Biroulet L.3, Filippi J.4, Pariente B.5, Roblin X.6, Buisson A.7, Stefanescu C.8, Trang-Poisson C.9, Altwegg R.10, Marteau P.11, Vaysse T.12, Bourrier A.13, Nancey S.14, Laharie D.15, Allez M.16, Bouhnik Y.8, Amiot A.17

1CHU Henri Mondor, Department of Gastroenterology, Creteil, France 2Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France 3CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France 4Archet 2 Hospital, Department of Gastroenterology, Nice, France 5CHRU Lille, Department of Gastroenterology, Lille, France 6University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France 7CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France 8APHP Beaujon, Department of Gastroenterology, Clichy, France 9CHU Hotel Dieu, Department of Gastroenterology, Nantes, France 10CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France 11Hospital Lariboisière, Department of Gastroenterology, Paris, France 12CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France 13APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France 14Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France 15CHU Bordeaux, Department of Gastroenterology, Bordeaux, France 16Hospital Saint-Louis, Department of Gastroenterology, Paris, France 17Henri Mondor Hospital, Gastroenterology, Creteil, France